CAIN45712301
|
abstract
|
A two-year, phase III randomized, double-blind, parallel- group,
placebo- controlled trial to evaluate the safety, efficacy, and
tolerability of 300 mg s.c. secukinumab versus placebo in
combination with SoC therapy in patients with active lupus nephritis
|
| |
|
|
type of project
|
clinical studies
|
|
status
|
ongoing - recruiting phase
|
|
start of project
|
2020
|
|
end of project
|
2022
|
|
study design
|
A pivotal, randomized, double- blind, placebo controlled trial
evaluating at week 52 the efficacy and safety of secukinumbab versus
placebo in subjects with active LN also receiving background SoC
regimen. Long- term efficacy, saftey and tolerability will be
collected up to 2 years.
|
|
responsible person
|
Prof. Andrea Rubbert-Roth
|
additional links & downloads
